Casdin Capital’s Fate Therapeutics FATE Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,050,000	Closed	-$7.67M	–	37
2023 Q4	$7.67M	Hold	2,050,000	–	–	0.75%	25
2023 Q3	$4.35M	Hold	2,050,000	–	–	0.48%	27
2023 Q2	$9.76M	Hold	2,050,000	–	–	0.85%	25
2023 Q1	$11.7M	Hold	2,050,000	–	–	0.96%	26
2022 Q4	$20.7M	Hold	2,050,000	–	–	1.6%	18
2022 Q3	$45.9M	Sell	2,050,000 -50,000	-2%	-$1.12M	3.02%	11
2022 Q2	$52M	Sell	2,100,000 -1,300,000	-38%	-$32.2M	4.4%	8
2022 Q1	$132M	Hold	3,400,000	–	–	5.91%	4
2021 Q4	$199M	Hold	3,400,000	–	–	5.61%	3
2021 Q3	$202M	Hold	3,400,000	–	–	5.02%	5
2021 Q2	$295M	Hold	3,400,000	–	–	7.49%	3
2021 Q1	$280M	Buy	3,400,000 +350,000	+11%	+$28.9M	8.35%	3
2020 Q4	$277M	Hold	3,050,000	–	–	8.22%	3
2020 Q3	$122M	Hold	3,050,000	–	–	5.46%	5
2020 Q2	$105M	Buy	3,050,000 +500,000	+20%	+$17.2M	6.19%	3
2020 Q1	$56.6M	Hold	2,550,000	–	–	6.01%	4
2019 Q4	$49.9M	Hold	2,550,000	–	–	4.59%	10
2019 Q3	$39.6M	Hold	2,550,000	–	–	4.1%	11
2019 Q2	$51.8M	Hold	2,550,000	–	–	4.85%	7
2019 Q1	$44.8M	Hold	2,550,000	–	–	4.92%	7
2018 Q4	$32.7M	Hold	2,550,000	–	–	5.6%	7
2018 Q3	$41.5M	Sell	2,550,000 -50,000	-2%	-$815K	5.05%	7
2018 Q2	$29.5M	Hold	2,600,000	–	–	4.12%	9
2018 Q1	$25.4M	Hold	2,600,000	–	–	4.46%	11
2017 Q4	$15.9M	Buy	2,600,000 +2,050,000	+373%	+$12.5M	3.87%	12
2017 Q3	$2.18M	Hold	550,000	–	–	0.62%	25
2017 Q2	$1.78M	Buy	+550,000	New	+$1.78M	0.66%	28